REMAP-CAPランダム化臨床試験における重症患者の長期 (180日) の結果
, Alisa M Higgins1, Lindsay R Berry2
1Monash University, Melbourne, Victoria, Australia.
JAMA
|December 16, 2022
まとめ
インタールイウキン-6 (IL-6) 受容体アンタゴニストは,重症のCOVID-19患者の6ヶ月の生存期間を有意に改善しました. 抗血小板薬も生存効果を示したが,回復期プラズマや特定の抗ウイルス薬などの他の治療法は無効または有害であることが判明した.
科学分野:
- クリティカル ケア 医療
- 感染症
- 薬理学について
背景:
- 重症のCOVID-19患者のために使用されている様々な治療法の長期的な効果は,ほとんど不明です.
- 治療戦略を最適化するには 介入の持続的な影響を理解することが重要です
研究 の 目的:
- COVID-19 の重症成人患者における複数の治療介入の長期的な (180日) 結果を評価する.
- 初期入院期間を超えた治療の有効性と安全性を決定する.
主な方法:
- 4869人の重症のCOVID-19患者を含むREMAP-CAP適応プラットフォーム試験の予め指定された二次分析.
- 患者は免疫調節薬,回復期プラズマ,抗血小板治療,抗凝固薬,抗ウイルス薬,およびコルチコステロイドを含む様々な治療領域にランダムに割り当てられました.
- ベイジアン統計モデルを用いて分析された主なアウトカムは180日生存率でした.
主要な成果:
- インタールイキン-6 (IL- 6) 受容体アンタゴニストは,6ヶ月の生存率を改善する確率> 99. 9% (調整HR,0. 74) を示した.
- 抗血小板薬は6ヶ月の生存率を95%改善した (調整HR,0. 85)
- 治療用抗凝固薬,回復期プラズマ,ロピナビル・リトナビルは高確率で無効であったが,ヒドロキシクロロキンとロピナビル・リトナビルの併用は有害であった.
結論:
- IL-6受容体アンタゴニストによる治療は,重症なCOVID-19患者の180日間の死亡率を大幅に改善します.
- 抗血小板療法も生存率を向上させる可能性がある.
- ほとんどの治療法の初期治療効果は6ヶ月間一貫しており,特定の介入の持続的な効果を強調しています.
関連する概念動画
01:21Acute Respiratory Failure-II
314
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
314
01:30Acute Respiratory Failure-III
262
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
262
01:28Acute Coronary Syndrome IV: Interprofessional Care
20
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
20
01:29Acute Respiratory Failure-V
181
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
181
01:26Acute Coronary Syndrome V: Nursing Management
24
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
24
01:28Pneumonia IV: Management
417
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
417